Oxford Biomedica 产品代理
Oxford Biomedica 产品代理
我们已经建立了行业领先的慢病毒载体交付系统，即LentiVector®平台，我们利用该平台在内部和与合作伙伴共同开发体内和体外产品。我们还在肿瘤学、眼科学、中枢神经系统疾病和肝脏疾病领域创建了一个宝贵的细胞和基因治疗候选产品专利组合。
LentiVector® platform
Pipeline
Bioprocessing
Oxford Biomedica is a leading, fully integrated, cell and gene therapy group
We have built a sector leading lentiviral vector delivery system, LentiVector® platform, which we leverage to develop in vivo and ex vivo products both in-house and with partners. We have also created a valuable proprietary portfolio of cell and gene therapy product candidates in the areas of oncology, ophthalmology, CNS disorders and liver diseases.
Oxford Biomedica has entered into a number of partnerships, including with Novartis, Juno Therapeutics/Bristol Myers Squibb, SIO Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations.
Additionally, we have a three-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine.
Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 740 people.
